Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2011

View Archived Issues

Novel CRAC inhibitors presented

New antibacterial aminoglycoside derivatives claimed

Merck & Co. patents new gamma-secretase inhibitors

Merrimack regains rights to nanoliposomal irinotecan from PharmaEngine

Favorable preclinical data disclosed on HSP 90 inhibitor MPC-3100

Compound 49b shows promise to treat diabetic retinopathy

Ophthalmic antimicrobial peptide SESB-88V inhibits ocular pathogens

Clinical study finds omalizumab ineffective in treating eosinophilic esophagitis

Intravenous solithromycin is well tolerated in healthy volunteers

Novel tyrosine-protein kinase JAK inhibitors patented by Pfizer

Rib-X Pharmaceuticals discloses new antibacterial agents

New ALK tyrosine kinase receptor inhibitors presented

Institute of Human Virology receives funding for HIV vaccine candidate FLSC

Opsona Therapeutics receives EC grant for clinical development of OPN-305

Chelsea Therapeutics receives approval to open new arm in phase II CH-4051 trial

Astellas and Medivation begin new phase II MDV-3100 trial in prostate cancer

MCD-386CR receives FDA orphan drug status in progressive supranuclear palsy

Wilex completes patient recruitment in phase II Mesupron trial

Alcon Research begins phase II study of AL-59412C

Takeda and Pronova report on pivotal Japanese trial of TAK-085 in hypertriglyceridemia

FDA approves Sanofi Pasteur's new intradermal injection of Fluzone influenza vaccine

Actikerall enters national approval phase in seven European countries for actinic keratosis

EpiCept files protocol for confirmatory phase III Ceplene trial in AML

Bayer's regorafenib receives FDA fast track status in GIST

CCL21-vaults have antitumor effects in model of lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 18, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...